Flupirtine maleate sustained release tablet

A flupirtine acid sustained-release tablet, flupirtine maleate technology, applied in the direction of nervous system diseases, active ingredients of heterocyclic compounds, drug combination, etc., can solve side effects, large fluctuations in blood drug concentration, Malay Short half-life of flupirtine and other problems to achieve the effect of relieving pain

Active Publication Date: 2013-09-25
SICHUAN BAILI PHARM CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Due to the short half-life of flupirtine maleate, common oral preparations need to be administered frequently (3-4 times a day, 100 mg each time), the blood concentration fluctuates greatly, and it is easy to produce obvious side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Flupirtine maleate sustained release tablet

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1: A flupirtine maleate sustained-release tablet, consisting of the following components (the coating weight of the sustained-release granules increases by 1%):

[0029] Flupirtine maleate immediate-release granules: (based on the amount of flupirtine maleate) 100g

[0030] Flupirtine maleate sustained-release granules: (based on the amount of flupirtine maleate) 300g

[0031] Sodium carboxymethyl starch 30g

[0032] Micronized silica gel 25g

[0033] Magnesium Stearate 5g

[0034] Microcrystalline Cellulose 20g

[0035] Among them, flupirtine maleate immediate-release granules consist of the following components:

[0036] Flupirtine Maleate 100g

[0037] Hypromellose (E50) 1g

[0038] Flupirtine maleate sustained-release granules are composed of the following components:

[0039] Flupirtine Maleate 300g

[0040] Hypromellose (E50) 9g

[0041] Microcrystalline Cellulose 30g

[0042] Eudragit NE30D 15ml

[0043] Calcium hydrogen phosphate 0.6g

[0044...

Embodiment 2

[0053] Example 2: A flupirtine maleate sustained-release tablet, consisting of the following components (the coating weight of sustained-release granules increased by 2%):

[0054] Flupirtine maleate immediate-release granules: (based on the amount of flupirtine maleate) 100g

[0055] Flupirtine maleate sustained-release granules: (according to the amount of flupirtine maleate) 300g

[0056] Sodium carboxymethyl starch 30g

[0057] Micronized silica gel 25g

[0058] Magnesium Stearate 5g

[0059]Microcrystalline Cellulose 20g

[0060] Among them, flupirtine maleate immediate-release granules consist of the following components:

[0061] Flupirtine Maleate 100g

[0062] Hypromellose (E50) 1g

[0063] Flupirtine maleate sustained-release granules are composed of the following components:

[0064] Flupirtine Maleate 300g

[0065] Hypromellose (E50) 9g

[0066] Microcrystalline Cellulose 30g

[0067] Eudragit NE30D 30ml

[0068] Calcium hydrogen phosphate 1.2g

[0069]...

Embodiment 3

[0071] Example 3: A flupirtine maleate sustained-release tablet, consisting of the following components (the coating weight of the sustained-release granules increases by 3%):

[0072] Flupirtine maleate immediate-release granules: (based on the amount of flupirtine maleate) 100g

[0073] Flupirtine maleate sustained-release granules: (according to the amount of flupirtine maleate) 300g

[0074] Sodium carboxymethyl starch 30g

[0075] Micronized silica gel 25g

[0076] Magnesium Stearate 5g

[0077] Microcrystalline Cellulose 20g

[0078] Among them, flupirtine maleate immediate-release granules consist of the following components:

[0079] Flupirtine Maleate 100g

[0080] Hypromellose (E50) 1g

[0081] Flupirtine maleate sustained-release granules are composed of the following components:

[0082] Flupirtine Maleate 300g

[0083] Hypromellose (E50) 9g

[0084] Microcrystalline Cellulose 30g

[0085] Eudragit NE30D 45ml

[0086] Calcium hydrogen phosphate 1.8g

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a flupirtine maleate sustained release tablet which is composed of the following ingredients of: by weight, 90-110 parts of flupirtine maleate intermediate-release particles, 290-310 parts of flupirtine maleate sustained release particles, 25-35 parts of sodium carboxymethyl starch, 20-30 parts of aerosol, 3-8 parts of magnesium stearate and 15-25 parts of microcrystalline cellulose. Weight proportions of the flupirtine maleate intermediate-release particles and the flupirtine maleate sustained release particles are both weighed according to the weight of flupirtine maleate.

Description

technical field [0001] The invention belongs to the technical field of chemical pharmacy and relates to a flupirtine maleate slow-release tablet. Background technique [0002] Flupirtine maleate (Chemical name: 2-amino-6-[(4-fluorobenzyl)amino]-3-pyridine carbamate ethyl ester maleate) opens selective neuronal potassium channels It is a non-opioid analgesic that acts on the central nervous system and does not produce dependence and tolerance. Flupirtine maleate activates G protein-coupled K on nerve cell membranes + Channel, K + Outflow stabilizes the resting membrane potential and reduces cell membrane activity, thereby indirectly inhibiting the activation of NMDA receptors. Flupirtine maleate at therapeutic concentrations does not bind to α1, α2, 5HT1, 5HT2, dopamine, benzodiazepines, opiates, central M and N receptors. Flupirtine maleate has three main effects on the central nervous system: analgesic effect, muscle relaxant effect, and the effect of preventing the per...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/44A61K9/26A61K47/38A61P25/04
Inventor 朱义龚涛王一茜廖彬
Owner SICHUAN BAILI PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap